Topical Ruxolitinib for the Treatment of Alopecia Universalis

    December 2015 in “ JAMA dermatology ”
    Brittany G. Craiglow, Daniel Tavares, Brett King
    TLDR Topical Ruxolitinib may safely treat severe hair loss.
    The document discussed the potential of topical Ruxolitinib as a treatment for Alopecia Universalis, a severe form of alopecia areata. While oral Janus kinase (JAK) inhibitors had been effective in treating these conditions, they carried risks of serious adverse effects. The study suggested that using a topical form of Ruxolitinib could mitigate these risks, offering a safer alternative for patients.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 1000+ results

      community What else is good. Besides the big 3.

      in Chat  35 upvotes 1 year ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community Ruxolitinib - Start of a case study

      in Research/Science  10 upvotes 1 year ago
      The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

      community Topical Finasteride Gel 1% after 4 months — problems

      in Finasteride  156 upvotes 1 day ago
      The user experienced hair thinning due to a testosterone spike and used a minoxidil solution and topical finasteride gel. After four months, the gel caused side effects without improving hair thinning, leading to questions about continuing or adjusting the treatment.

      community Topical dutasteride significantly outperforms oral finasteride

      in Research/Science  65 upvotes 2 weeks ago
      Topical dutasteride 0.05% is reported to outperform oral finasteride with minimal side effects, but concerns about study bias exist due to company funding. Some users report mixed results with topical dutasteride, noting issues with skin penetration and systemic absorption.

    Related Research

    3 / 3 results